Clinical experiences with hydrocortisone 17-butyrate.
In a double-blind comparative study, by 29 dermatological departments, the activity of hydrocortisone 17-butyrate (HC 17-B, Locoid), triamcinolone acetonide (TA) 0.1% and hydrocortisone 21-acetate (HA) 1%, were compared in patients suffering from acute eczematous dermatitis, atopic dematitis and psoriasis. After a 7-day period of observation, the results were evaluated by means of a chi2 test, and an Armitage tests. The following results were obtained: in acute eczematous dermatitis HC 17-B was found to be superior to the placebo and equal to TA; in atopic dermatitis HC 17-B was found to be superior to the placebo and HA,  equal to TA; in psoriasis vulgaris HC 17-B was found to be superior to the placebo, HA and TA.
D000208:Acute Disease; D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004341:Drug Evaluation; D004485:Eczema / Q000188:drug therapy*; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives*; D010919:Placebos; D011565:Psoriasis / Q000188:drug therapy*; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D010919:Placebos; D014222:Triamcinolone Acetonide; D006854:Hydrocortisone